Abstract
Despite improvements for management of type 1 diabetes (T1D), patients have difficulty achieving glycated hemoglobin (A1c) levels recommended by the Diabetes Control and Complications Trial (DCCT). Two multicenter randomized trials were conducted to evaluate benefit of using a continuous glucose monitor (CGM) with standard glucose monitoring for T1D management. The primary study evaluated benefits of CGM in 322 patients with A1c >7.0 %. The secondary study evaluated 129 patients with A1c <7.0 %. In the primary study, CGM resulted in improvements in A1c at 6 m in subjects >25 years, but not those <25. However, all subjects using CGM regularly showed benefit. Improved A1c did not come with increased severe hypoglycemia as seen in the DCCT, and benefit was sustained over 1 year. In the secondary study, CGM use helped subjects maintain target A1c levels with reduced exposure to biochemical hypoglycemia. The data collected allowed for other analyses of important factors in T1D management.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 380-387 |
| Number of pages | 8 |
| Journal | Journal of cardiovascular translational research |
| Volume | 5 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2012 |
Keywords
- Continuous glucose monitoring
- Glycated hemoglobin
- Hypoglycemia
- Psychosocial factors
- Type 1 diabetes